ArticleJournal of clinical laboratory analysis2026
Is Geenius HCV Supplemental Assay an Alternative to HCV Confirmatory Western Blot INNO-LIA HCV Score in Repeatedly Reactive Blood Donations After First Line Screening?
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is Geenius HCV Supplemental Assay an Alternative to HCV Confirmatory Western Blot INNO-LIA HCV Score in Repeatedly Reactive Blood Donations After First Line Screening?Journal of clinical laboratory analysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe objective of this study is to evaluate whether the rapid lateral flow immunochromatography Geenius HCV Supplemental Assay (ICH) can serve as an alternative to INNO-LIA HCV Score Confirmatory western blot (WB) assay in a population of blood donors.
methodsSera of 60 blood donors, anti-HCV antibodies repeatedly reactive after first line screening with Architect anti-HCV chemiluminescent immunoassay, (ABBOTT, Wiesbaden, Germany) (ICL) were evaluated for anti-HCV antibodies with Geenius HCV Supplemental assay (Bio-Rad. Marnes-la-Coquette-France) (ICH) and Inno-LIA HCV Score (Inogenetics NV. Gent. Belgium) (Inno-LIA WB). The level of agreement between ICH and WB results was determined by kappa statistics.
resultsOut of 60 samples identified as anti-HCV antibodies repeatedly reactive by ICL, ICH identified 32% samples as reactive and 2% as indeterminate. WB identified 35% samples as positive and 20% as indeterminate. Kappa analysis detected moderate agreement between ICH and WB in detecting anti-HCV antibodies (kappa = 0.60). Moderate to almost very good agreement is acknowledged between ICH and WB in reactivity with individual HCV antigens.
conclusionGiven the limited number of samples analyzed in this study we can summarize that Geenius HCV Supplemental and Inno-LIA WB assays are comparable pertaining to anti-HCV positive samples, but with discrepancy in results occurring in the area of samples classified with WB assay as indeterminate. However, there is very good agreement between Inno-LIA WB and Geenius ICH positivity/reactivity with individual HCV antigens. Our findings indicate that Geenius ICH Supplemental test cannot replace anti-HCV Inno-LIA WB in confirming anti-HCV antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.